The top two single-site targets for miR-16 are an Activin type II receptor gene (TGFbeta signaling) and Hox-A5, both known to be dysregulated at the level of protein expression in colon cancers (Wang et al. 2001). Here, TGFB1 is linked to malignant colon neoplasm.